Daniel Carlat, MD. Medical Director of Inpatient Psychiatry/Chairman of Psychiatry at Melrose Wakefield Healthcare. Publisher, Carlat Publishing.

Dr. Carlat has no financial relationships with companies related to this material.

Mark L. Ruffalo, MSW, DPsa. Editor in Chief, The Carlat Psychotherapy Report, psychotherapist in private practice in Tampa, Florida, and Assistant Professor of Psychiatry at the University of Central Florida College of Medicine and Adjunct Instructor of Psychiatry at Tufts University School of Medicine. He has broad clinical experience in the psychoanalytic treatment of mood, personality, and psychosomatic disorders, and has particular interest in the psychotherapy of schizophrenia and borderline personality disorder.

Dr. Ruffalo has no financial relationships with companies related to this material.

Kyle T. Greenway, MD, MSc.

Assistant Professor of Psychiatry at McGill University. Director of the ketamine-assisted therapy program at Jewish General Hospital, Montreal, Canada.

Dr. Greenway has no financial relationships with companies related to this material.

David Mintz, MD.

Fellow, American Academy of Psychoanalysis and Dynamic Psychiatry. Staff psychiatrist, Austen Riggs Center, Stockbridge, MA. 

Dr. Mintz has no financial relationships with companies related to this material.

Jeremy Mills, DNP, PHNP-BC, and Anthony Charuvastra, MD. The authors have no financial relationships with companies related to this material.

Thanos Karatzias, PsyDip, MSc, PhD, CPsychol. Edinburgh Napier University, School of Health & Social Care, Edinburgh, Scotland.

Dr. Karatzias has no financial relationships with companies related to this material.